B型利钠肽与心肌肌钙蛋白用于晕厥诊断和风险分层
这项前瞻性多中心诊断研究纳入1538例>45岁急诊晕厥患者,评估BNP、NT-proBNP、hs-cTnT和hs-cTnI对心源性晕厥的诊断和预后价值。四种生物标志物诊断心源性晕厥的AUC为0.77-0.78,优于EGSYS评分(AUC 0.68),联合利钠肽与肌钙蛋白可将AUC提升至0.81;预后预测AUC为0.75-0.79,优于ROSE、OESIL和SFSR,但劣于CSRS。
要点
- BNP、NT-proBNP、hs-cTnT、hs-cTnI对心源性晕厥诊断AUC为0.77-0.78,优于EGSYS评分。
- 利钠肽联合肌钙蛋白可将诊断AUC提升至0.81。
- 生物标志物预后预测AUC为0.75-0.79,优于ROSE、OESIL、SFSR,但劣于CSRS。
核心结论
- BNP、NT-proBNP、hs-cTnT和hs-cTnI浓度可为急诊晕厥患者提供有用的诊断和预后信息。
研究设计与样本
- 前瞻性诊断多中心研究,纳入>45岁急诊晕厥患者,最终1538例纳入诊断评估。
- 以2名医生基于所有可用信息(包括心脏检查和1年随访)裁定的心源性晕厥为诊断终点。
- 以30天和720天死亡及主要不良心血管事件为预后终点。
主要发现
- 1538例可诊断评估患者中,234例(15.2%)被裁定为心源性晕厥。
- 心源性晕厥患者BNP、NT-proBNP、hs-cTnT和hs-cTnI浓度显著高于其他原因晕厥(P<0.01)。
- 四种生物标志物诊断心源性晕厥的AUC均为0.77-0.78(95%CI 0.74-0.81),优于EGSYS评分(AUC 0.68,95%CI 0.65-0.71,P<0.001)。
- BNP/NT-proBNP联合hs-cTnT/hs-cTnI可将诊断AUC进一步提升至0.81(P<0.01)。
- 随访期间共发生450例主要不良心血管事件,四种生物标志物预后预测AUC为0.75-0.79,优于ROSE、OESIL和SFSR,但劣于CSRS。
关键数值与推荐
- BNP、NT-proBNP、hs-cTnT和hs-cTnI达到预设敏感性和特异性(95%)阈值时,可对约30%的患者进行纳入或排除。
- 主要不良心血管事件定义为死亡、心肺复苏、危及生命的心律失常、起搏器/植入式心律转复除颤器植入、急性心肌梗死、肺栓塞、卒中/短暂性脑缺血发作、颅内出血或瓣膜手术。
临床怎么用
- 急诊>45岁晕厥患者可检测BNP、NT-proBNP、hs-cTnT或hs-cTnI辅助诊断心源性晕厥并进行风险分层。
- 联合利钠肽与肌钙蛋白可提高诊断准确性。
- 生物标志物预后预测优于ROSE、OESIL和SFSR,但不如CSRS。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The utility of BNP (B-type natriuretic peptide), NT-proBNP (N-terminal proBNP), and hs-cTn (high-sensitivity cardiac troponin) concentrations for diagnosis and risk-stratification of syncope is incompletely understood. METHODS: We evaluated the diagnostic and prognostic accuracy of BNP, NT-proBNP, hs-cTnT, and hs-cTnI concentrations, alone and against those of clinical assessments, in patients >45-years old presenting with syncope to the emergency department in a prospective diagnostic multicenter study. BNP, NT-proBNP, hs-cTnT and hs-cTnI concentrations were measured in a blinded fashion. Cardiac syncope, as adjudicated by 2 physicians based on all information available including cardiac work-up and 1-year follow-up, was the diagnostic end point. EGSYS (Evaluation of Guidelines in Syncope Study), a syncope-specific diagnostic score, served as the diagnostic comparator. Death and major adverse cardiac events at 30 and 720 days were the prognostic end points. Major adverse cardiac events were defined as death, cardiopulmonary resuscitation, life-threatening arrhythmia, implantation of pacemaker/implantable cardioverter defibrillator, acute myocardial infarction, pulmonary embolism, stroke/transient ischemic attack, intracranial bleeding, or valvular surgery. ROSE (Risk Stratification of Syncope in the Emergency Department), OESIL (Osservatorio Epidemiologico della Sincope nel Lazio), SFSR (San Fransisco Syncope Rule), and CSRS (Canadian Syncope Risk Score) served as the prognostic comparators. RESULTS: Among 1538 patients eligible for diagnostic assessment, cardiac syncope was the adjudicated diagnosis in 234 patients (15.2%). BNP, NT-proBNP, hs-cTnT, and hs-cTnI were significantly higher in cardiac syncope versus other causes (P<0.01). The diagnostic accuracy for cardiac syncope, as quantified by the area under the curve, was 0.77 to 0.78 (95% CI, 0.74-0.81) for all 4 biomarkers, and superior to EGSYS (area under the curve, 0.68 [95%-CI 0.65-0.71], P<0.001). Combining BNP/NT-proBNP with hs-cTnT/hs-cTnI further improved diagnostic accuracy to an area under the curve of 0.81 (P<0.01). BNP, NT-proBNP, hs-cTnT, and hs-cTnI cut-offs, achieving predefined thresholds for sensitivity and specificity (95%), allowed for rule-in or rule-out of ≈30% of all patients. A total of 450 major adverse cardiac events occurred during follow-up. The prognostic accuracy of BNP, NT-proBNP, hs-cTnI, and hs-cTnT for major adverse cardiac events was moderate-to-good (area under the curve, 0.75-0.79), superior to ROSE, OESIL, and SFSR, and inferior to CSRS. CONCLUSIONS: BNP, NT-proBNP, hs-cTnT, and hs-cTnI concentrations provide useful diagnostic and prognostic information in emergency department patients with syncope. CLINICAL TRIAL REGISTRATION: URL: https://www. CLINICALTRIALS: gov. Unique identifier: NCT01548352.
引用
- du Fay de Lavallaz J, Badertscher P, Nestelberger T, et al. B-Type Natriuretic Peptides and Cardiac Troponins for Diagnosis and Risk-Stratification of Syncope. Circulation. 2019. PMID: 30798615. doi:10.1161/CIRCULATIONAHA.118.038358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。